Infant Bacterial Announces Phase III IBP-9414 Study Results

About this update from Infant Bacterial Therapeutics Ab Class B

Infant Bacterial Therapeutics AB OMXSTO:IBT_B:ANNOUNCES PHASE III STUDY RESULTS PUBLISHED IN PEDIATRIC RESEARCHPHASE III STUDY SHOWS 27% MORTALITY REDUCTION WITH IBP-9414TREATMENT DESIGNATED AS 'BREAKTHROUGH THERAPY' AND 'RARE PAEDIATRIC DISEASE'STUDY CONCLUDES IBP-9414 REDUCES MORTALITY AND NECROTIZING ENTEROCOLITIS

View stock analysis, news, and events for Infant Bacterial Therapeutics Ab Class B